David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared Herbert Loong’s, Advisor at Greater Bay Area International Clinical Trial Institute, and Steering Committee Member at Lung Cancer Policy Network, post on LinkedIn, adding:
“A shared pleasure and a superb meeting discussing the incredible advances in HER2-mutant NSCLC with next-generation ADCs and HER2-TKIs.
A major step forward for our patients! Emphasizing the need to test the best treatment sequencing, understand resistance mechanisms, and systematically screen patients (HER2 mut and overexpression).
Thanks for the incredible welcome in HK as always!”
Quoting Herbert Loong‘s post:
“Always a pleasure to welcome David Planchard to Hong Kong! Thanks for sharing with us your insights in contemporary management of HER2positive NSCLC. Had excellent discussions with local thoracic oncology experts in the field.”
Other articles featuring David Planchard and Herbert Loong on OncoDaily.